News | February 16, 2022
Moderna announces expansion in key Asian markets
New subsidiaries to be established in Malaysia, Taiwan, Singapore, and Hong Kong
New subsidiaries to be established in Malaysia, Taiwan, Singapore, and Hong Kong
Apexxnar is the first pneumococcal conjugate vaccine to help protect adults ages 18 years and older against 20 serotypes responsible for the majority of invasive disease and pneumococcal pneumonia
The capex during the last nine months has been around Rs 110 crores which is all funded through internal accruals
Through this acquisition, Ayu Health will add 1000 beds to provide localised primary and tertiary medical care for citizens of Jaipur
The device will facilitate the treatment of cerebral vasospasm following hemorrhagic stroke
The entire integration and transition of the brands is expected to be completed by March 2022
BDR Pharmaceuticals is a home-grown company with operations in India and overseas. It’s known for its formulations portfolio and has a presence in specialty medicines. The company has ambitious plans as it has ramped up capacity and looking to foray into regulated markets. Raheel Shah, Director, BDR Group of Companies shares his insights in an interview with Thomas C Thottathil, Editor, Indian Pharma Post
These results will be presented on 17 February at the 2022 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium
The recommendation has been sent to the DCGI for approval
Last year, the company's early-stage breast cancer detection test became the first such test to receive the Breakthrough Device Designation
Subscribe To Our Newsletter & Stay Updated
